IL-17 and limits of success

•Overview of autoimmune diseases that are treated by the blockade of IL-17.•Overview of autoimmune diseases that are unresponsive to IL-17 blockade.•Updates on ongoing and recently completed clinical trials targeting IL-17.•Expanding the efficacy of IL-17 blockade through other autoimmune diseases....

Full description

Saved in:
Bibliographic Details
Published in:Cellular immunology 2019-05, Vol.339, p.33-40
Main Authors: Omidian, Zahra, Ahmed, Rizwan, Giwa, Adebola, Donner, Thomas, Hamad, Abdel Rahim A.
Format: Article
Language:English
Subjects:
Animals
Autoimmune diseases
Autoimmune Diseases - immunology
Clinical trials
Humans
IL-17
Immunotherapy
Immunotherapy - methods
Inflammatory Bowel Diseases - immunology
Interleukin-17
Interleukin-17 - immunology
Multiple Sclerosis - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Overview of autoimmune diseases that are treated by the blockade of IL-17.•Overview of autoimmune diseases that are unresponsive to IL-17 blockade.•Updates on ongoing and recently completed clinical trials targeting IL-17.•Expanding the efficacy of IL-17 blockade through other autoimmune diseases. Interleukin-17 (IL-17) is a potent proinflammatory cytokine that protects a host against fungal and extracellular bacterial infections. On the other hand, excessive or dysregulated production of IL-17 underlines susceptibility to autoimmune disease. Consequently, blocking IL-17 has become an effective strategy for modulating several autoimmune diseases, including multiple sclerosis (MS), psoriasis, and rheumatoid arthritis (RA). Notably, however, IL-17 blockade remains ineffective or even pathogenic against important autoimmune diseases such as inflammatory bowel disease (IBD). Furthermore, the efficacy of IL-17 blockade against other autoimmune diseases, including type 1 diabetes (T1D) is currently unknown and waiting results of ongoing clinical trials. Coming years will determine whether the efficacy of IL-17 blockade is limited to certain autoimmune diseases or can be expanded to other autoimmune diseases. These efforts include new clinical trials aimed at testing second-generation agents with the goal of increasing the efficiency, spectrum, and ameliorating side effects of IL-17 blockade. Here we briefly review the roles of IL-17 in the pathogenesis of selected autoimmune diseases and provide updates on ongoing and recently completed trials of IL-17 based immunotherapies.
ISSN:0008-8749
1090-2163
DOI:10.1016/j.cellimm.2018.09.001